New document clarifies confusion over hormone therapy for women
A new position statement from NAMS provides the latest science on the risks and benefits of hormone therapy for postmenopausal women.
The North American Menopause Society (NAMS) has released updated clinical recommendations for hormone therapy (HT) for postmenopausal women. NAMS claims its latest position statement is based on the most recent evidence in the literature. Entitled “Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society,” the document was developed by an advisory panel of 14 women’s health experts and then approved by the NAMS board. NAMS said that a lot of fear and confusion has surrounded HT recently and its document clears up this confusion.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, click here.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
Assessing Financial Impacts of Pharmacist-Led Interventions in Pediatric Ambulatory Care
December 5th 2023According to a poster abstract presented at the ASHP Midyear Clinical Meeting & Exhibition, specialty pharmacy services were used for a variety of conditions that have been reported in adult populations.
